Replies to post #137337 on Biotech Values

[genisi]

BCX-4208 safety

Do you see concern that even the lower doses, such as 10mg, would see issues with drops in CD4+ counts as we go beyond 24 weeks or is 24 weeks a reasonable length of time to think this might be a reasonable dose for the drug going forward? Note, again, that even with reductions in CD4+ in the higher arms, the AEs, including infections, were similar across all dosing groups.

Safety profile for the lower doses looks better as lymphocyte plateau reached by 12 weeks of treatment remained unchanged and vaccine challenge results were fine and infections were similar in the placebo. So immunosuppression beyond 24 weeks might be tolerated with the low doses.